Acelyrin (SLRN) News Today → Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (From Paradigm Press) (Ad) Free slrn Stock Alerts $4.18 -0.18 (-4.13%) (As of 06/14/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 10, 2024 | marketbeat.comSuperstring Capital Management LP Makes New Investment in Acelyrin, Inc. (NASDAQ:SLRN)Superstring Capital Management LP bought a new position in shares of Acelyrin, Inc. (NASDAQ:SLRN - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 356,924 shares of the company's stock, valued at approximately $2,663,000. Acelyrin makes upJune 8, 2024 | marketbeat.comSectoral Asset Management Inc. Buys Shares of 325,549 Acelyrin, Inc. (NASDAQ:SLRN)Sectoral Asset Management Inc. purchased a new stake in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 325,549 shares of the company's stock, valued at approxiJune 1, 2024 | marketbeat.comAcelyrin, Inc. (NASDAQ:SLRN) Sees Significant Decline in Short InterestAcelyrin, Inc. (NASDAQ:SLRN - Get Free Report) saw a significant drop in short interest during the month of May. As of May 15th, there was short interest totalling 7,020,000 shares, a drop of 17.7% from the April 30th total of 8,530,000 shares. Currently, 11.2% of the shares of the company are short sold. Based on an average daily volume of 1,160,000 shares, the days-to-cover ratio is presently 6.1 days.May 30, 2024 | marketbeat.comDecheng Capital LLC Purchases New Position in Acelyrin, Inc. (NASDAQ:SLRN)Decheng Capital LLC purchased a new stake in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 1,370,951 shares of the company's stock, valued at approximately $10,227,000. Acelyrin makes upMay 29, 2024 | globenewswire.comACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024May 24, 2024 | marketbeat.comQ2 2024 EPS Estimates for Acelyrin, Inc. (NASDAQ:SLRN) Increased by HC WainwrightAcelyrin, Inc. (NASDAQ:SLRN - Free Report) - Investment analysts at HC Wainwright raised their Q2 2024 earnings per share estimates for Acelyrin in a report released on Wednesday, May 22nd. HC Wainwright analyst E. Bodnar now expects that the company will post earnings of ($0.33) per share for thMay 22, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) PT Raised to $18.00HC Wainwright boosted their price objective on shares of Acelyrin from $16.00 to $18.00 and gave the stock a "buy" rating in a research note on Wednesday.May 18, 2024 | finance.yahoo.comAcelyrin, Inc. (SLRN)May 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for ACELYRIN, INC. on Solid Financials and Promising PipelineMay 15, 2024 | investorplace.comSLRN Stock Earnings: Acelyrin Beats EPS for Q1 2024May 15, 2024 | markets.businessinsider.comACELYRIN, INC.: Strong Buy Recommendation on Promising Izo Drug Prospects and Strategic AdvancementsMay 9, 2024 | marketwatch.comAcelyrin Founder Steps Down as CEOMay 9, 2024 | msn.comAcelyrin names Mina Kim as new Chief Executive OfficerMay 9, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Price Target Cut to $18.00HC Wainwright dropped their price objective on Acelyrin from $28.00 to $18.00 and set a "buy" rating for the company in a report on Thursday.May 9, 2024 | finance.yahoo.comACELYRIN, INC. Announces Leadership TransitionMay 9, 2024 | globenewswire.comACELYRIN, INC. Provides Business Update and Highlights Key Upcoming MilestonesMay 6, 2024 | marketbeat.comAcelyrin (SLRN) to Release Earnings on MondayAcelyrin (NASDAQ:SLRN) will be releasing earnings after the market closes on Monday, May 13, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=591359)April 29, 2024 | globenewswire.comACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024April 19, 2024 | marketbeat.comVontobel Holding Ltd. Purchases Shares of 325,549 Acelyrin, Inc. (NASDAQ:SLRN)Vontobel Holding Ltd. acquired a new position in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 325,549 shares of the company's stock, valued at approximately $2,429,000. Vontobel Holding Ltd. owned about 0.3April 17, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Hits New 12-Month Low at $5.10Acelyrin (NASDAQ:SLRN) Sets New 1-Year Low at $5.10April 16, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Shares Down 5.1% Acelyrin (NASDAQ:SLRN) Trading Down 5.1%April 14, 2024 | marketbeat.comAcelyrin, Inc. (NASDAQ:SLRN) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Acelyrin, Inc. (NASDAQ:SLRN - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven research firms that are covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating and four have given a buyApril 10, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Hits New 12-Month Low at $5.61Acelyrin (NASDAQ:SLRN) Sets New 12-Month Low at $5.61April 3, 2024 | marketbeat.comAcelyrin, Inc. Forecasted to Earn Q2 2024 Earnings of ($0.82) Per Share (NASDAQ:SLRN)Acelyrin, Inc. (NASDAQ:SLRN - Free Report) - Research analysts at HC Wainwright issued their Q2 2024 EPS estimates for shares of Acelyrin in a research report issued on Monday, April 1st. HC Wainwright analyst E. Bodnar expects that the company will earn ($0.82) per share for the quarter. HC WainApril 2, 2024 | marketbeat.comResearch Analysts Issue Forecasts for Acelyrin, Inc.'s Q1 2024 Earnings (NASDAQ:SLRN)Acelyrin, Inc. (NASDAQ:SLRN - Free Report) - HC Wainwright issued their Q1 2024 EPS estimates for shares of Acelyrin in a report issued on Monday, April 1st. HC Wainwright analyst E. Bodnar expects that the company will post earnings of ($0.86) per share for the quarter. HC Wainwright currentlyApril 1, 2024 | msn.comStocks Pressured as Bond Yields Jump on Strength in US ManufacturingApril 1, 2024 | markets.businessinsider.comACELYRIN, INC.: Promising Clinical Trials and Market Opportunity Justify Buy RatingApril 1, 2024 | marketbeat.comAcelyrin's (SLRN) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $28.00 target price on shares of Acelyrin in a research note on Monday.March 28, 2024 | investorplace.comSLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023March 28, 2024 | finance.yahoo.comACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent HighlightsMarch 28, 2024 | globenewswire.comACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent HighlightsMarch 21, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Shares Down 6.3% Acelyrin (NASDAQ:SLRN) Stock Price Down 6.3%March 21, 2024 | marketbeat.comWells Fargo & Company Raises Acelyrin (NASDAQ:SLRN) Price Target to $13.00Wells Fargo & Company raised their price objective on shares of Acelyrin from $11.00 to $13.00 and gave the stock an "equal weight" rating in a report on Thursday.March 20, 2024 | markets.businessinsider.comBuy Rating on ACELYRIN, INC.: Promising Clinical Prospects for Novel TED Therapy LonigutamabMarch 20, 2024 | markets.businessinsider.comAcelyrin Announces Positive Phase 1/2 Data For Lonigutamab In Thyroid Eye Disease; Stock UpMarch 20, 2024 | msn.comInvestors Cheer Acelyrin's Stock, Its Second Lead Candidate Shows Clinical Benefit In Thyroid Eye Disease PatientsMarch 20, 2024 | finance.yahoo.comACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye DiseaseMarch 20, 2024 | marketbeat.comAcelyrin, Inc. (NASDAQ:SLRN) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of Acelyrin, Inc. (NASDAQ:SLRN - Get Free Report) have earned an average rating of "Moderate Buy" from the seven research firms that are covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendatMarch 20, 2024 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Acelyrin (NASDAQ:SLRN)HC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of Acelyrin in a research report on Wednesday.March 18, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Shares Gap Down to $7.84Acelyrin (NASDAQ:SLRN) Shares Gap Down to $7.84March 18, 2024 | finance.yahoo.comSLRN Apr 2024 2.500 putMarch 15, 2024 | marketbeat.comWalleye Capital LLC Acquires New Stake in Acelyrin, Inc. (NASDAQ:SLRN)Walleye Capital LLC acquired a new stake in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 447,355 shares of the company's stock, valued at approximately $4,550,000. Walleye Capital LLC owned approximately 0March 12, 2024 | seekingalpha.comAcelyrin: Analyzing Its Recovery And Potential In Psoriatic ArthritisMarch 12, 2024 | markets.businessinsider.comHold Rating Affirmed for ACELYRIN, INC. as Izokibep Faces Competitive Hurdles and Safety ConcernsMarch 12, 2024 | marketbeat.comAdage Capital Partners GP L.L.C. Sells 270,000 Shares of Acelyrin, Inc. (NASDAQ:SLRN)Adage Capital Partners GP L.L.C. lessened its holdings in shares of Acelyrin, Inc. (NASDAQ:SLRN - Free Report) by 73.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 100,000 shares of the company's stMarch 11, 2024 | marketwatch.comAcelyrin Stock Climbs 10% on Positive Results for Arthritis TreatmentMarch 11, 2024 | msn.comAcelyrin's Lead Drug Candidate Hits Primary Goal In Late-Stage Psoriatic Arthritis StudyMarch 11, 2024 | markets.businessinsider.comAcelyrin's Phase2b/3 Trial Of Izokibep In Psoriatic Arthritis Meets Primary EndpointMarch 11, 2024 | globenewswire.comACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic ArthritisMarch 11, 2024 | globenewswire.comACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients Get Acelyrin News Delivered to You Automatically Sign up to receive the latest news and ratings for SLRN and its competitors with MarketBeat's FREE daily newsletter. Email Address The attacks will come for me after releasing this… (Ad)America’s “Internal Enemies” Exposed New documentary exposes a hidden election plan in Washington D.C. that, if successful, could be more financially and culturally devastating than the dot-com blowup of 2000, the 2008 financial crisis, or the COVID crash. Click here to see how you can protect yourself today. SLRN Media Mentions By Week SLRN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SLRN News Sentiment▼1.830.89▲Average Medical News Sentiment SLRN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SLRN Articles This Week▼33▲SLRN Articles Average Week Get Acelyrin News Delivered to You Automatically Sign up to receive the latest news and ratings for SLRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: KURA News SNDX News EWTX News TARO News DVAX News ARDX News MORF News SUPN News LGND News AKRO News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SLRN) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | Sponsored